Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Studie zur Vorbeugung chronischer Migräne durch Vorhersage des Ansprechens auf die Behandlung mit Anti-CGRP-Antikörpern (PREDI-CGRP)

Vorhersagestudie oder Reaktion auf die Behandlung mit monoklonalen Anti-CGRP-Antikörpern bei Migräne

Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The study consists of an initial visit coinciding with the start of treatment, a subsequent visit after 6 months of treatment and finally another after 12 months, coinciding with the end of treatment. In case of worsening after suspension, a clinical visit will be carried out at the time of worsening to evaluate the reintroduction of the drug and in case of reintroduction, a visit will be carried out after 3 months. If patients do not worsen, a visit will be made 6 months after completing treatment.

At each visit, demographic and clinical variables will be collected. In addition, 3 blood tests will be performed corresponding to the beginning of treatment, after 6 months and a month and a half from the last infiltration. Likewise, a brain MRI will be obtained prior to the start of treatment. These blood samples and neuroimaging data will be processed for subsequent analysis.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

350

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Aragon
      • Zaragoza, Aragon, Spanien, 50009
        • Hospital Clínico Universitario Lozano Blesa
    • Basque Country
      • Donostia / San Sebastian, Basque Country, Spanien, 20014
        • Hospital Universitario Donostia
    • Cantabria
      • Santander, Cantabria, Spanien, 39008
        • Hospital Universitario Marqués de Valdecilla
    • Castille and León
      • Valladolid, Castille and León, Spanien, 47010
        • Hospital Clínico Universitario de Valladolid
    • Catalonia
      • Barcelona, Catalonia, Spanien, 08035
        • Hospital Universitari Vall d'Hebron Research Institute
    • Madrid
      • Madrid, Madrid, Spanien, 28006
        • Hospital Universitario de La Princesa
    • Valencia
      • Valencia, Valencia, Spanien, 46026
        • Hospital Universitario Politécnico La Fe

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients aged between 18 and 65 years with a diagnosis of episodic or chronic migraine who, at the discretion of their neurologist and according to clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or its receptor (Erenumab) be included. These patients will come from 7 Headache Units in Spain belonging to the following hospitals:

  • La Princesa University Hospital
  • Vall d'Hebron University Hospital
  • Marqués de Valdecilla University Hospital
  • Valladolid University Clinical Hospital
  • Donostia University Hospital
  • Lozano Blesa University Clinical Hospital
  • La Fe Polytechnic University Hospital

Beschreibung

Inclusion Criteria:

  • Patients aged between 18 and 65 years.
  • Caucasian ethnicity.
  • Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
  • Have at least one year of history of migraine.
  • Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
  • Patients able to describe their clinical situation and the characteristics of their headache.
  • Grant your informed consent.

Exclusion Criteria:

  • Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
  • Neurological focus in the examination.
  • Pregnancy or breastfeeding period.
  • Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
  • Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
  • Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Patients with migraine under treatment with monoclonal antibodies against CGRP

Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included.

The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication.

Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.

Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Biomarkers of positive initial response to monoclonal antibodies
Zeitfenster: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

Establish clinical, demographic, transcriptomic, genetic, molecular and/or radiological characteristics that allow predicting a positive initial response to monoclonal antibodies (biomarkers of therapeutic response).

From the beginning of treatment, which is the initial visit, to 18 months of follow-up

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Sustained response factors
Zeitfenster: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To analyze sustained response factors at the sociodemographic, clinical, transcriptomic, genetic, molecular and/or radiological level after the suspension of anti-CGRP drugs.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up
Sustained response after discontinuation of the anti-CGRP antibody
Zeitfenster: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To quantify the proportion of patients who present a sustained response after discontinuation of the anti-CGRP antibody.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up
Non-maintained pharmacological response relation with biomarkers
Zeitfenster: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To characterize whether the non-maintained pharmacological response is related to the variables previously characterized as predictors of chronicity.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up
Time until relapse after discontinuation of the anti-CGRP antibody
Zeitfenster: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To determine the time until relapse after discontinuation of the anti-CGRP monoclonal antibody in those patients who, having presented a positive initial response, discontinue it.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up
Biomarkers of patients with high-frequency episodic migraine and chronic migraine
Zeitfenster: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To validate possible transcriptomic, genetic, molecular and/or radiological characteristics that allow differentiation between patients with high-frequency episodic migraine and chronic migraine in a national multicenter cohort.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

26. April 2023

Primärer Abschluss (Tatsächlich)

31. Juli 2026

Studienabschluss (Geschätzt)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

5. Juni 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. Juni 2024

Zuerst gepostet (Tatsächlich)

14. Juni 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

25. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. September 2026

Zuletzt verifiziert

1. Januar 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • PI 23- 3054

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.

Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .